Verona pharma announces amended strategic financing with oaktree and omers

Ripsa interests repurchased term loan facility increased to $450 million with more favorable terms access to up to an additional $200 million london and raleigh, n.c., march 28, 2025 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“ripsa”) and increasing the debt facility to $450 million on improved terms with funds managed by oaktree capital management, l.p.
VRNA Ratings Summary
VRNA Quant Ranking